Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death

뉴스 본문을 불러오고 있어요.

Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death | 웨이프 WAPE

Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death

기사 요약

관련 종목

댓글 —